Head-to-head evidence
AV000103A (ICVAX) vs BNT168
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV antigens · full HIV pipeline
AV000103A (ICVAX)
Developed by Immuno Cure BioTech
NCT06253533 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: March 2027 · NCT07530198 (registry estimate)
BNT168
Developed by BioNTech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2028 · NCT07698600 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV000103A (ICVAX)'s landscape · BNT168's landscape